Interaction Checker

Interaksi Bosutinib

Bosutinib (Bosulif) memiliki 79 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 65 mayor, 14 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (65)

  • AmiodaronantiaritmiaMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • AtazanavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • DarunavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • DronedaronantiaritmiaMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • EtravirinantiretroviralMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • EverolimusimunosupresanMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Flukonazolantijamur azolMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • GriseofulvinantijamurMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • IsoniazidantibiotikMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • LenakapavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • NefazodonantidepresanMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • NevirapinantiretroviralMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • PerampanelantikonvulsanMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Posakonazolantijamur azolMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • RifabutinantibiotikMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • RifampisinantibiotikMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • RifapentinantibiotikMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • RitonavirantiretroviralMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • SiklosporinimunosupresanMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • TikagrelorantiplateletMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    • Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (label Bosutinib, Interaksi obat)

Interaksi moderat (14)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Dekslansoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Esomeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Famotidinpenghambat H2Moderat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Lansoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Naproksen dan esomeprazolOAINSModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Natrium bikarbonatantasidaModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Nizatidinpenghambat H2Moderat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Omeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Pantoprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Rabeprazolpenghambat pompa protonModerat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

  • Ranitidinpenghambat H2Moderat

    Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (label Bosutinib, Interaksi obat)

Periksa Bosutinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.